Literature DB >> 36254731

Changing patterns of multidisciplinary team treatment, early mortality, and survival in colorectal cancer.

David M Layfield1, Karen G Flashman1, Sara Benitez Majano2, Asha Senapati1, Christopher Ball1, John A Conti1, Jim S Khan1, Daniel P O'Leary1.   

Abstract

BACKGROUND: This study reports early mortality and survival from colorectal cancer in relation to the pattern of treatments delivered by the multidisciplinary team (MDT) meeting at a high-volume institution in England over 14 years.
METHODS: All patients diagnosed with colorectal cancer and discussed during MDT meetings from 2003 to 2016 at a single institution were reviewed. Three time intervals (2003-2007, 2008-2012, and 2013-2016) were compared regarding initial surgical management (resection, local excision, non-resection surgery, and no surgery), initial oncological therapy, 90-day mortality, and crude 2-year survival for the whole cohort. Sub-analyses were performed according to age greater or less than 80 years.
RESULTS: The MDT managed 4617 patients over 14 years (1496 in the first interval and 1389 in the last). Over this time, there was a reduction in emergency resections from 15.5 per cent to 9.0 per cent (P < 0.0001); use of oncological therapies increased from 34.6 per cent to 41.6 per cent (P < 0.0001). The 90-day mortality after diagnosis of colorectal cancer dropped from 14.8 per cent to 10.7 per cent (P < 0.001) and 2-year survival improved from 58.6 per cent to 65 per cent (P < 0.001). Among patients aged 80 years or older (425 and 446, in the first and last intervals respectively) there was, in addition, a progressive increase in 'no surgery' rate from 33.6 per cent to 50.2 per cent (P < 0.0001) and a reduction in elective resections from 42.4 per cent to 33.9 per cent (P = 0.010). The 90-day mortality after elective resection fell from 10.0 per cent (18 of 180) to 3.3 per cent (5 of 151; P = 0.013).
CONCLUSIONS: Survival from colorectal cancer improved significantly over 14 years. Among patients aged ≥80 years, major changes in the type of treatment delivered were associated with a decrease in postoperative mortality.
© The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd.

Entities:  

Mesh:

Year:  2022        PMID: 36254731      PMCID: PMC9577547          DOI: 10.1093/bjsopen/zrac098

Source DB:  PubMed          Journal:  BJS Open        ISSN: 2474-9842


  22 in total

1.  Primacy of surgery for colorectal cancer.

Authors:  J Liang; V Fazio; I Lavery; F Remzi; T Hull; S Strong; J Church
Journal:  Br J Surg       Date:  2015-04-02       Impact factor: 6.939

2.  Frailty in older patients undergoing emergency colorectal surgery: USA National Surgical Quality Improvement Program analysis.

Authors:  H L Simon; T Reif de Paula; M M Profeta da Luz; S K Nemeth; S J Moug; D S Keller
Journal:  Br J Surg       Date:  2020-07-08       Impact factor: 6.939

3.  Frailty predicts severe postoperative complications after elective colorectal surgery.

Authors:  Hirohisa Okabe; Takayuki Ohsaki; Katsuhiro Ogawa; Nobuyuki Ozaki; Hiromitsu Hayashi; Shinichi Akahoshi; Yoshiaki Ikuta; Kenichi Ogata; Hideo Baba; Hiroshi Takamori
Journal:  Am J Surg       Date:  2018-11-23       Impact factor: 2.565

4.  Quality improvement in multidisciplinary cancer teams: an investigation of teamwork and clinical decision-making and cross-validation of assessments.

Authors:  B W Lamb; N Sevdalis; H Mostafid; C Vincent; J S A Green
Journal:  Ann Surg Oncol       Date:  2011-05-19       Impact factor: 5.344

5.  Stage at diagnosis and colorectal cancer survival in six high-income countries: a population-based study of patients diagnosed during 2000-2007.

Authors:  Camille Maringe; Sarah Walters; Bernard Rachet; John Butler; Tony Fields; Paul Finan; Roy Maxwell; Bjørn Nedrebø; Lars Påhlman; Annika Sjövall; Allan Spigelman; Gerda Engholm; Anna Gavin; Marianne L Gjerstorff; Juanita Hatcher; Tom B Johannesen; Eva Morris; Colleen E McGahan; Elizabeth Tracey; Donna Turner; Michael A Richards; Michel P Coleman
Journal:  Acta Oncol       Date:  2013-04-15       Impact factor: 4.089

Review 6.  Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013.

Authors:  D Papamichael; R A Audisio; B Glimelius; A de Gramont; R Glynne-Jones; D Haller; C-H Köhne; S Rostoft; V Lemmens; E Mitry; H Rutten; D Sargent; J Sastre; M Seymour; N Starling; E Van Cutsem; M Aapro
Journal:  Ann Oncol       Date:  2014-07-11       Impact factor: 32.976

7.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

Authors:  E Van Cutsem; A Cervantes; R Adam; A Sobrero; J H Van Krieken; D Aderka; E Aranda Aguilar; A Bardelli; A Benson; G Bodoky; F Ciardiello; A D'Hoore; E Diaz-Rubio; J-Y Douillard; M Ducreux; A Falcone; A Grothey; T Gruenberger; K Haustermans; V Heinemann; P Hoff; C-H Köhne; R Labianca; P Laurent-Puig; B Ma; T Maughan; K Muro; N Normanno; P Österlund; W J G Oyen; D Papamichael; G Pentheroudakis; P Pfeiffer; T J Price; C Punt; J Ricke; A Roth; R Salazar; W Scheithauer; H J Schmoll; J Tabernero; J Taïeb; S Tejpar; H Wasan; T Yoshino; A Zaanan; D Arnold
Journal:  Ann Oncol       Date:  2016-07-05       Impact factor: 32.976

8.  Identifying patients at risk of emergency admission for colorectal cancer.

Authors:  D Wallace; K Walker; A Kuryba; P Finan; N Scott; J van der Meulen
Journal:  Br J Cancer       Date:  2014-06-12       Impact factor: 7.640

9.  Variation in the Use of Resection for Colorectal Cancer Liver Metastases.

Authors:  Hayley M Fenton; John C Taylor; J Peter A Lodge; Giles J Toogood; Paul J Finan; Alastair L Young; Eva J A Morris
Journal:  Ann Surg       Date:  2019-11       Impact factor: 12.969

10.  Management of colorectal cancer explains differences in 1-year relative survival between France and England for patients diagnosed 1997-2004.

Authors:  O Dejardin; B Rachet; E Morris; V Bouvier; V Jooste; R Haynes; E G Coombes; D Forman; A P Jones; A M Bouvier; G Launoy
Journal:  Br J Cancer       Date:  2013-02-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.